GleamWall
中文EN

OCEA Ocean Biomedical, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1869974 · Fiscal year ends 12/31

Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY1.6%
TTM EPS YoY6.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,276.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5,940.6%
Debt / equity—
Current ratio0.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.14x
Accruals ratio-1,097.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-30
Income statement
Revenue————————
R&D expense$18,000$0$0$0$26,000-$17,000$305,000$28,000
SG&A expense$940,000$1.75M$768,000$682,000$569,000-$643,000$2.35M$2.80M
Operating income-$958,000-$1.75M-$768,000-$682,000-$595,000$660,000-$2.65M-$2.83M
Interest expense$343,000——-$337,000$637,000$13,148$0$24,046
Net income-$8.24M$283,000-$3.70M-$17.23M$13.00M-$16.86M-$14.09M-$11.43M
EPS (basic)-0.09—-0.13-0.630.48—-0.53-0.43
EPS (diluted)-0.09—-0.13-0.630.48—-0.53-0.43
Weighted avg. shares (diluted)91.02M—27.49M27.49M27.34M—26.61M26.47M
Banking
Net interest income—-$433,000-$461,000-$515,000-$637,000-$500,000-$293,000-$668,000
Balance sheet
Cash & equivalents$800,000$200,000$200,000$200,000$19,000$4,000$1.00M$1.10M
Current assets$1.49M$812,000$1.04M$1.28M$1.80M$2.11M$1.03M$2.16M
Total assets$1.58M$902,000$1.13M$1.85M$2.95M$5.50M$1.03M$2.16M
Current liabilities$26.57M$33.89M$31.82M$30.74M$30.11M$30.01M$30.85M$29.79M
Short-term debt—————$3.20M—$11.87M
Total liabilities$93.98M$98.52M$97.39M$94.59M$78.73M$96.26M$76.25M$63.82M
Shareholders' equity-$92.40M-$97.62M-$96.26M-$92.74M-$75.78M-$90.76M-$75.22M-$61.66M
Shares outstanding166.01M34.87M34.87M34.87M34.82M34.65M34.09M34.01M
Cash flow statement
Operating cash flow-$356,000-$2.52M-$885,000-$290,000-$485,000-$866,000-$1.13M-$4.78M
Financing cash flow$909,000$2.50M———$839,000$0$6.64M
Stock-based compensation$186,000$186,000$186,000$187,000$186,000$187,000$186,000$186,000

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.